AU2001258395A1 - Formulations containing a glucocorticoid drug for the treatment of bronchopulmonary diseases - Google Patents

Formulations containing a glucocorticoid drug for the treatment of bronchopulmonary diseases

Info

Publication number
AU2001258395A1
AU2001258395A1 AU2001258395A AU5839501A AU2001258395A1 AU 2001258395 A1 AU2001258395 A1 AU 2001258395A1 AU 2001258395 A AU2001258395 A AU 2001258395A AU 5839501 A AU5839501 A AU 5839501A AU 2001258395 A1 AU2001258395 A1 AU 2001258395A1
Authority
AU
Australia
Prior art keywords
treatment
formulations containing
bronchopulmonary diseases
glucocorticoid drug
glucocorticoid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001258395A
Inventor
Gaetano Brambilla
Alessandra Ferraris
David Ganderton
David Lewis
Brian Meakin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiesi Farmaceutici SpA
Original Assignee
Chiesi Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farmaceutici SpA filed Critical Chiesi Farmaceutici SpA
Publication of AU2001258395A1 publication Critical patent/AU2001258395A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
AU2001258395A 2000-05-12 2001-05-08 Formulations containing a glucocorticoid drug for the treatment of bronchopulmonary diseases Abandoned AU2001258395A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT2000MI001051A IT1318514B1 (en) 2000-05-12 2000-05-12 FORMULATIONS CONTAINING A GLUCOCORTICOSTEROID DRUG FOR THE TREATMENT OF BRONCOPOLMONARY DISEASES.
ITMI200A001051 2000-05-12
PCT/EP2001/005211 WO2001085174A1 (en) 2000-05-12 2001-05-08 Formulations containing a glucocorticoid drug for the treatment of bronchopulmonary diseases

Publications (1)

Publication Number Publication Date
AU2001258395A1 true AU2001258395A1 (en) 2001-11-20

Family

ID=11445031

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001258395A Abandoned AU2001258395A1 (en) 2000-05-12 2001-05-08 Formulations containing a glucocorticoid drug for the treatment of bronchopulmonary diseases

Country Status (21)

Country Link
US (1) US20030190289A1 (en)
EP (1) EP1280532A1 (en)
JP (1) JP2004515454A (en)
AR (1) AR028448A1 (en)
AU (1) AU2001258395A1 (en)
BG (1) BG107257A (en)
CA (1) CA2408647A1 (en)
CZ (1) CZ20023717A3 (en)
EA (1) EA200201059A1 (en)
EE (1) EE200200632A (en)
HR (1) HRP20020893A2 (en)
HU (1) HUP0302036A2 (en)
IT (1) IT1318514B1 (en)
MA (1) MA26899A1 (en)
MX (1) MXPA02011132A (en)
NO (1) NO20025394L (en)
PE (1) PE20011271A1 (en)
PL (1) PL366212A1 (en)
SK (1) SK16062002A3 (en)
TN (1) TNSN01071A1 (en)
WO (1) WO2001085174A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
DZ2947A1 (en) 1998-11-25 2004-03-15 Chiesi Farma Spa Pressure metered dose inhaler.
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
IT1313553B1 (en) 1999-07-23 2002-09-09 Chiesi Farma Spa OPTIMIZED FORMULATIONS CONSTITUTED BY SOLUTIONS OF STEROIDS GIVEN BY INHALATION.
IT1317720B1 (en) * 2000-01-07 2003-07-15 Chiesi Farma Spa DEVICE FOR THE ADMINISTRATION OF AEROSOL DOSED PRESSURIZED INPROPELLENT HYDROFLUOROALKANS.
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
ME00220B (en) * 2000-05-22 2010-10-10 Chiesi Farm Spa Stable pharmaceutical solution formulations for pressurised metered dose inhalers
TR200401980T4 (en) * 2001-07-02 2004-09-21 Chiesi Farmaceutici S.P.A. Tobramycin formulation optimized for aerosol administration
EP1340492A1 (en) * 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Aerosol formulations for pulmonary administration of medicaments having systemic effects
PT3494995T (en) * 2002-03-01 2020-03-30 Chiesi Farm Spa Formoterol superfine formulation
EP1415647A1 (en) * 2002-10-23 2004-05-06 CHIESI FARMACEUTICI S.p.A. "Long-acting beta-2 agonists ultrafine formulations"
US20040265238A1 (en) * 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
EP1595531A1 (en) 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
WO2012007729A2 (en) * 2010-07-16 2012-01-19 Cipla Limited Pharmaceutical compositions
WO2015195711A2 (en) * 2014-06-16 2015-12-23 Shurtleff, James, Kevin Method and devices for manufacturing and delivering of aerosolized formulations

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3361306A (en) * 1966-03-31 1968-01-02 Merck & Co Inc Aerosol unit dispensing uniform amounts of a medically active ingredient
US3622053A (en) * 1969-12-10 1971-11-23 Schering Corp Aerosol inhaler with flip-up nozzle
US4185100A (en) * 1976-05-13 1980-01-22 Johnson & Johnson Topical anti-inflammatory drug therapy
US4499108A (en) * 1983-06-08 1985-02-12 Schering Corporation Stable pleasant-tasting albuterol sulfate pharmaceutical formulations
GB8334494D0 (en) * 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
IT1196142B (en) * 1984-06-11 1988-11-10 Sicor Spa PROCEDURE FOR THE PREPARATION OF 16.17-ACETALS OF PREGNANIC DERIVATIVES AND NEW COMPOUNDS OBTAINED
US4584320A (en) * 1985-01-03 1986-04-22 David Rubin Anti-asthmatic composition and method using 8,11,14,17-eicosatetraenoic acid
US5192528A (en) * 1985-05-22 1993-03-09 Liposome Technology, Inc. Corticosteroid inhalation treatment method
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US6006745A (en) * 1990-12-21 1999-12-28 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
EP0601036B1 (en) * 1991-08-29 1999-04-28 Broncho-Air Medizintechnik AG Medical device for inhalating doses of spray
US5683676A (en) * 1991-12-12 1997-11-04 Glaxo Group Limited Canister containing aerosol formulations containing P134a and particulate medicaments
DE4230876A1 (en) * 1992-03-17 1993-09-23 Asta Medica Ag COMPRESSED GAS PACKS USING POLYOXYETHYLENE GLYCERYL OLEATES
AU6048694A (en) * 1992-12-09 1994-07-04 Paul D. Jager Stabilized medicinal aerosol solution formulations
SE9203743D0 (en) * 1992-12-11 1992-12-11 Astra Ab EFFICIENT USE
AU4066693A (en) * 1992-12-23 1994-07-19 Bernhard Hugemann Compacted drug body for use in the mechanical generation of inhalable active-substance particles
EP0735884B1 (en) * 1993-12-20 2000-04-26 Minnesota Mining And Manufacturing Company Flunisolide aerosol formulations
US5653961A (en) * 1995-03-31 1997-08-05 Minnesota Mining And Manufacturing Company Butixocort aerosol formulations in hydrofluorocarbon propellant
WO1996032150A1 (en) * 1995-04-14 1996-10-17 Glaxo Wellcome Inc. Metered dose inhaler for salmeterol
EP1166811B1 (en) * 1995-04-14 2006-12-06 SmithKline Beecham Corporation Metered dose inhaler for fluticasone propionate
DK0820279T3 (en) * 1995-04-14 2002-10-07 Smithkline Beecham Corp Dosing metered inhaler for Albuterol
GEP20002266B (en) * 1995-04-14 2000-10-25 Glaxo Wellcome Inc Metered Dose Inhaler, the Inhaler System Comprising the Same and Method for Treatment of Respiratory Disturbances
JP2728057B2 (en) * 1995-10-30 1998-03-18 日本電気株式会社 Information access device for optical disk
US6039932A (en) * 1996-09-27 2000-03-21 3M Innovative Properties Company Medicinal inhalation aerosol formulations containing budesonide
US6413496B1 (en) * 1996-12-04 2002-07-02 Biogland Ireland (R&D) Limited Pharmaceutical compositions and devices for their administration
US5891419A (en) * 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe flunisolide aerosol formulations for oral inhalation
GB2326334A (en) * 1997-06-13 1998-12-23 Chiesi Farma Spa Pharmaceutical aerosol compositions
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US5954047A (en) * 1997-10-17 1999-09-21 Systemic Pulmonary Development, Ltd. Methods and apparatus for delivering aerosolized medication
US6045784A (en) * 1998-05-07 2000-04-04 The Procter & Gamble Company Aerosol package compositions containing fluorinated hydrocarbon propellants
SE9802073D0 (en) * 1998-06-11 1998-06-11 Astra Ab New use
US6451285B2 (en) * 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
US6241969B1 (en) * 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
NZ509328A (en) * 1998-07-24 2002-11-26 Jago Res A Medicinal aerosol formulations
DE19847969A1 (en) * 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Stable liquid formulation of formoterol in solution or suspension medium, used after dilution for treatment of asthma by inhalation
DK1283036T3 (en) * 1998-11-13 2008-03-25 Jagotec Ag Dry powder for inhalation
DZ2947A1 (en) * 1998-11-25 2004-03-15 Chiesi Farma Spa Pressure metered dose inhaler.
IT1303788B1 (en) * 1998-11-25 2001-02-23 Chiesi Farma Spa MEDICINAL AEROSOL FORMULATIONS.
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
US6290930B1 (en) * 1998-12-18 2001-09-18 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes and budesonide
GB9902689D0 (en) * 1999-02-08 1999-03-31 Novartis Ag Organic compounds
SK286981B6 (en) * 1999-03-05 2009-08-06 Chiesi Farmaceutici S.P.A. Powder for use in a dry powder inhaler, carrier for the powder and method for the production of powder
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
IT1317846B1 (en) * 2000-02-22 2003-07-15 Chiesi Farma Spa FORMULATIONS CONTAINING AN ANTICOLINERGIC DRUG FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE BRONCOPNEUMOPATHY.
ME00220B (en) * 2000-05-22 2010-10-10 Chiesi Farm Spa Stable pharmaceutical solution formulations for pressurised metered dose inhalers
PT3494995T (en) * 2002-03-01 2020-03-30 Chiesi Farm Spa Formoterol superfine formulation
EP1415647A1 (en) * 2002-10-23 2004-05-06 CHIESI FARMACEUTICI S.p.A. "Long-acting beta-2 agonists ultrafine formulations"
EP1340492A1 (en) * 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Aerosol formulations for pulmonary administration of medicaments having systemic effects

Also Published As

Publication number Publication date
PE20011271A1 (en) 2002-01-11
CA2408647A1 (en) 2001-11-15
EA200201059A1 (en) 2003-04-24
MA26899A1 (en) 2004-12-20
BG107257A (en) 2003-06-30
NO20025394D0 (en) 2002-11-11
SK16062002A3 (en) 2003-04-01
MXPA02011132A (en) 2003-04-25
EP1280532A1 (en) 2003-02-05
PL366212A1 (en) 2005-01-24
WO2001085174A1 (en) 2001-11-15
TNSN01071A1 (en) 2005-11-10
HUP0302036A2 (en) 2003-09-29
EE200200632A (en) 2004-04-15
AR028448A1 (en) 2003-05-07
JP2004515454A (en) 2004-05-27
ITMI20001051A0 (en) 2000-05-12
NO20025394L (en) 2003-01-13
IT1318514B1 (en) 2003-08-27
CZ20023717A3 (en) 2003-04-16
HRP20020893A2 (en) 2004-02-29
ITMI20001051A1 (en) 2001-11-12
US20030190289A1 (en) 2003-10-09

Similar Documents

Publication Publication Date Title
AU2180400A (en) A pharmaceutical combination for the treatment of depression
AU2001249329A1 (en) Lipoxin analogs and methods for the treatment of periodontal disease
AU6900200A (en) System for fabrication of indirect dental restoratives
AU2001235691A1 (en) Use of paullone derivatives for making medicines
AU7031500A (en) Therapeutic quinazoline compounds
AU2001276860A1 (en) Medicaments for chemotherapeutic treatment of disease
AU4949800A (en) 2-arylpurine-9-acetamide derivatives, process for the preparation thereof, medicinal compositions containing the same and intermediates of the derivatives
AU3009801A (en) Combinations of medicaments for treating viral diseases
AU2001258395A1 (en) Formulations containing a glucocorticoid drug for the treatment of bronchopulmonary diseases
AU2177001A (en) Use of indirubine derivatives for making medicines
AU2003249105A1 (en) Processes for the preparation of oral dosage formulations of modafinil
AU6858996A (en) Pharmaceutical compositions for the treatment of infectious diseases
AU7728698A (en) Oral formulations for treatment of bacteria-induced diseases of the colon
AU2002338303A1 (en) Therapeutic compositions for the treatment of a respiratory tract disease
AU2670600A (en) Pharmaceutical composition containing desoxypeganine for the treatment of nicotine dependence
AU3945501A (en) Apparatus for dosage of medicaments
AU1732401A (en) Medicinal compositions for oral use
AU7449698A (en) Therapeutic agents for respiratory diseases
AU1405001A (en) Treatment of diseases
AU2002210286A1 (en) Medicine intended for treatment of multiple sclerosis
AU2001279649A1 (en) Use of organophosphorous hydroxamic acid derivatives for producing medicaments
AU2003247001A1 (en) Processes for the preparation of oral dosage formulations of modafinil
AU2001274000A1 (en) Optically active 2-aminotetralin derivatives, the processes for the preparation thereof and the therapeutical use of pharmaceutical compositions containing them
AU2001271026A1 (en) Remedies for bone diseases
AU2001262520A1 (en) Combined preparation for the treatment of neoplasic diseases